Source 1primary paper2026MED
Toolkit/cell-free systems-based high-throughput screening
cell-free systems-based high-throughput screening
Also known as: CFS-based HTS
Taxonomy: Technique Branch / Method. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
This chapter explores the principles, platforms, and applications of CFS-based HTS... Altogether, CFS-based HTS offers a flexible, rapid, and accessible approach for next-generation biomolecular screening and therapeutic development.
Usefulness & Problems
Why this is useful
CFS-based HTS uses in vitro transcription-translation systems to express and screen biomolecules in parallel. The abstract presents it as a flexible screening approach for large biomolecular libraries.; parallel screening of biomolecule libraries; rapid in vitro expression and testing from DNA or RNA templates; synthetic biology, drug discovery, diagnostics, and protein engineering applications
Source:
CFS-based HTS uses in vitro transcription-translation systems to express and screen biomolecules in parallel. The abstract presents it as a flexible screening approach for large biomolecular libraries.
Source:
parallel screening of biomolecule libraries
Source:
rapid in vitro expression and testing from DNA or RNA templates
Source:
synthetic biology, drug discovery, diagnostics, and protein engineering applications
Problem solved
It addresses limitations of live-cell HTS by removing constraints from cellular physiology, including toxicity and metabolic interference. This enables rapid and tunable in vitro screening.; avoids cellular toxicity, metabolic interference, and regulatory constraints associated with live-cell HTS
Source:
It addresses limitations of live-cell HTS by removing constraints from cellular physiology, including toxicity and metabolic interference. This enables rapid and tunable in vitro screening.
Source:
avoids cellular toxicity, metabolic interference, and regulatory constraints associated with live-cell HTS
Problem links
This is an explicitly high-throughput screening method in cell-free systems, so it plausibly reduces manual handling and supports more standardized screening workflows. Its fit is strongest for the throughput side of the gap.
We Can’t Yet Replicate Animal Olfaction Synthetically as a Sensing and Classification Modality
Gap mapView gapA major bottleneck in the gap is mapping many receptor-odorant interactions, and this item is explicitly a rapid, flexible high-throughput screening approach. It could plausibly help generate large binding or functional datasets needed for odor decoding models if adapted to olfactory receptor assays.
The gap explicitly calls for combinatorial screening approaches, and this item is an actionable high-throughput assay method for rapidly testing compounds, nucleic acids, or proteins. It could support early-stage screening of intervention combinations before moving into more physiological models.
The gap may require rapid discovery of new biomolecular countermeasures, and this item is explicitly a rapid, accessible high-throughput screening platform for therapeutic development. It could plausibly accelerate finding candidate transmission-blocking molecules or biologics, but the supplied evidence is not specific to pathogens, surfaces, aerosols, or PPE materials.
avoids cellular toxicity, metabolic interference, and regulatory constraints associated with live-cell HTS
LiteratureIt addresses limitations of live-cell HTS by removing constraints from cellular physiology, including toxicity and metabolic interference. This enables rapid and tunable in vitro screening.
Source:
It addresses limitations of live-cell HTS by removing constraints from cellular physiology, including toxicity and metabolic interference. This enables rapid and tunable in vitro screening.
Published Workflows
Objective: Use cell-free systems to perform high-throughput screening of biomolecules by expressing and testing large libraries in vitro.
Why it works: The abstract states that cell-free systems remove constraints imposed by living cells and allow rapid, tunable biomolecule expression directly from nucleic acid templates, while integration with high-throughput platforms and sensitive readouts enables scalable multiplexed screening.
in vitro transcription-translation from DNA or RNA templatescircumvention of cellular physiological constraintshigh-throughput screeningmicroplatesdroplet microfluidicspaper-based devicesfluorescence readoutluminescence readoutmass spectrometry readoutdigital PCR readoutrobotic liquid handlingdata-driven DBTL cyclesmachine learning
Taxonomy & Function
Primary hierarchy
Technique Branch
Method: A concrete measurement method used to characterize an engineered system.
Target processes
diagnosticrecombinationselectiontranscriptiontranslationInput: Chemical
Implementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: sensor
The method requires cell-free transcription-translation machinery, DNA or RNA templates, and a high-throughput assay format such as microplates, droplet microfluidics, or paper-based devices. It also uses analytical readouts such as fluorescence, luminescence, mass spectrometry, or digital PCR.; requires reconstituted transcription-translation machinery; requires compatible high-throughput platform and analytical readout
The abstract notes that reagent cost and limited post-translational modifications remain challenges. It therefore does not eliminate all practical or biochemical constraints.; high reagent costs; limited post-translational modifications
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Cell-free systems-based high-throughput screening avoids limitations of live-cell high-throughput screening such as cellular toxicity, metabolic interference, and regulatory constraints.
Traditionally conducted in live cells, HTS faces limitations such as cellular toxicity, metabolic interference, and regulatory constraints. Cell-free systems (CFS), which operate in vitro using reconstituted transcription-translation machinery, have emerged as powerful alternatives.
Cell-free systems-based high-throughput screening has applications in synthetic biology, drug discovery, diagnostics, and protein engineering.
This chapter explores the principles, platforms, and applications of CFS-based HTS, highlighting its transformative impact on synthetic biology, drug discovery, diagnostics, and protein engineering.
Cell-free systems allow rapid and tunable expression of biomolecules directly from DNA or RNA templates.
These systems circumvent the constraints of cellular physiology, allowing for rapid and tunable expression of biomolecules directly from DNA or RNA templates.
Lyophilized cell-free kits, artificial cells, and AI-integrated closed-loop platforms are expanding the frontiers of cell-free high-throughput screening.
innovations such as lyophilized CFS kits, artificial cells, and AI-integrated closed-loop platforms are expanding the frontiers of HTS.
Cell-free high-throughput screening remains limited by high reagent costs and limited post-translational modifications.
Despite challenges such as high reagent costs and limited post-translational modifications...
Integration of cell-free systems with microplates, droplet microfluidics, and paper-based devices enables cost-effective, scalable, and multiplexed assays.
The integration of CFS with high-throughput platforms such as microplates, droplet microfluidics, and paper-based devices enables cost-effective, scalable, and multiplexed assays.
Fluorescence, luminescence, mass spectrometry, and digital PCR can provide real-time, sensitive detection of biochemical outputs in cell-free high-throughput screening.
Analytical readouts, including fluorescence, luminescence, mass spectrometry, and digital PCR, provide real-time, sensitive detection of biochemical outputs.
Automation and machine learning incorporated through robotic liquid handling and data-driven DBTL cycles accelerate discovery and design processes in cell-free high-throughput screening.
Furthermore, automation and machine learning are increasingly incorporated through robotic liquid handling and data-driven DBTL cycles, accelerating discovery and design processes.
Approval Evidence
1 source8 linked approval claimsfirst-pass slug cell-free-systems-based-high-throughput-screening
This chapter explores the principles, platforms, and applications of CFS-based HTS... Altogether, CFS-based HTS offers a flexible, rapid, and accessible approach for next-generation biomolecular screening and therapeutic development.
Source:
advantagesupports
Cell-free systems-based high-throughput screening avoids limitations of live-cell high-throughput screening such as cellular toxicity, metabolic interference, and regulatory constraints.
Traditionally conducted in live cells, HTS faces limitations such as cellular toxicity, metabolic interference, and regulatory constraints. Cell-free systems (CFS), which operate in vitro using reconstituted transcription-translation machinery, have emerged as powerful alternatives.
Source:
application scopesupports
Cell-free systems-based high-throughput screening has applications in synthetic biology, drug discovery, diagnostics, and protein engineering.
This chapter explores the principles, platforms, and applications of CFS-based HTS, highlighting its transformative impact on synthetic biology, drug discovery, diagnostics, and protein engineering.
Source:
capabilitysupports
Cell-free systems allow rapid and tunable expression of biomolecules directly from DNA or RNA templates.
These systems circumvent the constraints of cellular physiology, allowing for rapid and tunable expression of biomolecules directly from DNA or RNA templates.
Source:
future directionsupports
Lyophilized cell-free kits, artificial cells, and AI-integrated closed-loop platforms are expanding the frontiers of cell-free high-throughput screening.
innovations such as lyophilized CFS kits, artificial cells, and AI-integrated closed-loop platforms are expanding the frontiers of HTS.
Source:
limitationsupports
Cell-free high-throughput screening remains limited by high reagent costs and limited post-translational modifications.
Despite challenges such as high reagent costs and limited post-translational modifications...
Source:
platform integrationsupports
Integration of cell-free systems with microplates, droplet microfluidics, and paper-based devices enables cost-effective, scalable, and multiplexed assays.
The integration of CFS with high-throughput platforms such as microplates, droplet microfluidics, and paper-based devices enables cost-effective, scalable, and multiplexed assays.
Source:
readout capabilitysupports
Fluorescence, luminescence, mass spectrometry, and digital PCR can provide real-time, sensitive detection of biochemical outputs in cell-free high-throughput screening.
Analytical readouts, including fluorescence, luminescence, mass spectrometry, and digital PCR, provide real-time, sensitive detection of biochemical outputs.
Source:
workflow accelerationsupports
Automation and machine learning incorporated through robotic liquid handling and data-driven DBTL cycles accelerate discovery and design processes in cell-free high-throughput screening.
Furthermore, automation and machine learning are increasingly incorporated through robotic liquid handling and data-driven DBTL cycles, accelerating discovery and design processes.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts CFS-based HTS with traditional live-cell high-throughput screening. It also mentions multiple cell-free platform formats rather than a single implementation.
Source:
The abstract contrasts CFS-based HTS with traditional live-cell high-throughput screening. It also mentions multiple cell-free platform formats rather than a single implementation.
Source-backed strengths
rapid and tunable expression of biomolecules directly from DNA or RNA templates; compatible with scalable and multiplexed high-throughput platforms; supports sensitive analytical readouts
Source:
rapid and tunable expression of biomolecules directly from DNA or RNA templates
Source:
compatible with scalable and multiplexed high-throughput platforms
Source:
supports sensitive analytical readouts
Compared with high throughput screening
The abstract contrasts CFS-based HTS with traditional live-cell high-throughput screening. It also mentions multiple cell-free platform formats rather than a single implementation.
Shared frame: source-stated alternative in extracted literature
Strengths here: rapid and tunable expression of biomolecules directly from DNA or RNA templates; compatible with scalable and multiplexed high-throughput platforms; supports sensitive analytical readouts.
Relative tradeoffs: high reagent costs; limited post-translational modifications.
Source:
The abstract contrasts CFS-based HTS with traditional live-cell high-throughput screening. It also mentions multiple cell-free platform formats rather than a single implementation.
Ranked Citations
- 1.